A serial, cross-sectional study has found that gabapentinoid medication use among adults with cancer in the United States has more than doubled over a recent 10-year period.
Culling data from the Medical Expenditure Panel Survey, the study (Support Care Cancer 2020;28[1]:5-8) concluded that the annual percentage of gabapentinoid users in this patient population was 3.28% in 2005, compared with 8.26% in 2015, representing a 2.39-fold increase (P=0.001).
The researchers had hypothesized an increase